Both clinicians and patients should be aware of the different management options in diabetic patients who have not responded to phosphodiesterase type 5 inhibitors.
No takes yet. Share an insight, caveat, or question.
Cayetano‐Alcaraz et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: